- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA Commends 340B Drug Discount Accountability Act
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration.
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act (HR 6240), introduced by Representative Chris Collins, R-New York, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration (HRSA).
The legislation will ensure that HRSA receives additional resources needed to properly oversee and administer the program, according to COA. The user fees would go toward program oversight, audits, and monitoring of the program.
Grantees and non-hospital covered entities would be exempt. The bill would also give HRSA “direct-hire authority” for new employees to implement and conduct the oversight.
Read more about the legislation and the full press release here.
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
